Drug Trial Radar · NCT04310215
Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus
Last checked: Nov 20, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Mar 3, 2020
Primary completion
Jun 13, 2022
Study completion Jun 13, 2022
Sponsor
- Lead sponsor
- Hyundai Bioland Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Medipost Co Ltd.
- First posted
- Mar 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect.
Conditions
- Chondral or Osteochondral Lesion of Talus
Interventions
CARTISTEM®Biological
\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠ 1. Procedure: Microfracture 2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)
MicrofractureProcedure
\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠ 1\. Procedure: Microfracture
Primary outcomes
What the sponsor says the trial is designed to measure.
- ICRS-Cartilage Repair Assessment Total ScoreTime frame: Week 48
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Kyunghee University Medical Center
Seoul, Dongdaemun-gu, South Korea
Gangnam Severance Hospital
Seoul, Gangnam-gu, South Korea
Samsung Medical Center
Seoul, Gangnam-gu, South Korea
Korea University Guro Hospital
Seoul, Guro-gu, South Korea
Chungnam National University Hospital
Daejeon, Jung-gu, South Korea
Inha University Hospital
Incheon, Jung-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.